Advertisement

Aggressivität der Ratte nach kombinierter Behandlung mit Monoaminoxydase-Inhibitoren und anderen psychotropen Pharmaka, insbesondere Thymoleptica

  • G. Zetler
  • U. Otten
Chapter

Zusammenfassung

  1. 1.

    Kombinierte Behandlung von Ratten mit MAO-Inhibitoren und tricyclischen Thymoleptica führte zu einem Erregungssyndrom mit Aggressivität. Allein gegeben waren MAO-Hemmer und Thymoleptica in dieser Hinsicht wirkungslos.

     
  2. 2.

    Die MAO-Inhibitoren waren untereinander nicht austauschbar: Phenelzin, Iproniazid und Isocarboxazid, aber nicht Harmalin, Pheniprazin, Pargylin und Tranylcypromin lösten in Kombination mit Imipramin Aggressivität aus.

     
  3. 3.

    Von sieben Thymoleptica riefen nur Imipramin und Amitriptylin, kombiniert mit Isocarboxazid, Aggressivität hervor; Cocain war wirkungslos, Amphetamin führte erst nach Isocarboxazid zu Aggressivität.

     
  4. 4.

    DL-DOPA erzeugte ohne und mit MAO-Hemmung Aggressivität, 5-Hydroxy-tryptophan war wirkungslos. Inhibitoren der Katecholamin-Synthese hemmten die Entstehung der Aggressivität.

     
  5. 5.

    Katecholamine und nicht 5-Hydroxytryptamin dürften bei der Entstehung der Aggressivität eine Rolle spielen.

     
  6. 6.

    Zentrale Erregung mit Hyperthermie einerseits und Aggressivität andererseits stehen wahrscheinlich nicht in kausaler Beziehung.

     

Schlüsselwörter

Aggressivität MAO-Inhibitoren Thymoleptica Katecholamine 

Summary

  1. 1.

    The combined treatment of rats with MAO-inhibitors and tricyclic thymoleptics caused a central excitation syndrome with aggressiveness. When given alone, MAO-inhibitors and thymoleptics were inactive in this respect.

     
  2. 2.

    Only phenelzine, iproniazid, and isocarboxazide elicited aggressiveness when combined with imipramine. Harmaline, pheniprazine, pargyline, and tranylcypromine were inactive.

     
  3. 3.

    Of seven thymoleptics, only imipramine and amitriptyline caused aggressiveness when given after isocarboxazide. Cocaine was not active. Amphetamine produced aggressiveness after isocarboxazide.

     
  4. 4.

    Aggressiveness was caused by DL -DOPA with and without MAO inhibition, 5-hydroxytryptophan was inactive. Inhibitors of catecholamine synthesis prevented the aggressiveness.

     
  5. 5.

    Catecholamines, but not 5-hydroxytryptamine, are supposed to play a part in the mechanism leading to aggressiveness.

     
  6. 6.

    Central excitation with hyperthermia on one hand, and aggressiveness on the other hand are probably not causally related.

     

Key-Words

Aggressiveness MAO-Inhibitors Thymoleptics Catecholamines 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Axelrod, J., G. Hertting, and R.W. Patrick: Inhibition of H3-norepinephrine release by monoamine oxidase inhibitors. J. Pharmacol. exp. Ther. 134, 325–328 (1961).PubMedGoogle Scholar
  2. Babiak, W.: Case fatality due to overdosage of a combination of tranylcypromine (parnate) and imipramine (tofranil). Canad. med. Ass. J. 85, 377 (1961).PubMedGoogle Scholar
  3. Barnett, S.A.: An analysis of social behaviour in wild rats. Proc. Zool. Soc. (Lond.) 130, 107–152 (1958).CrossRefGoogle Scholar
  4. Bickel, M.H.: Untersuchungen zur Biochemie und Pharmakologie der Thymoleptika. Fortschr. Arzneimittel-Forsch. 11, 121–225 (1968).Google Scholar
  5. Biel, J.H., A. Horita, and A.E. Drukkeb: Monoamine oxidase inhibitors (hydrazines). In: Medicinal Chemistry, Psychopharmacological Agents (ed. M. Gobdon), Vol. 1, pp. 359–443. New York-London: Academic Press 1964.Google Scholar
  6. Boudin, G., et A. Laubas: Quelques observations illustrant les dangers des antidépresseurs IMAO. Bull. Soc. méd. Hôp. Paris 116, 479–486 (1965).PubMedGoogle Scholar
  7. Brodie, B.B., M.H. Bickel, and F. Sulser: Desmethyl imipramine, a new type of antidepressant drug. Med. exp. (Basel) 5, 454–458 (1961).CrossRefGoogle Scholar
  8. Carlsson, A., and M. Lindqvist: Metatyrosine as a tool for selective protection of catecholamine stores against reserpine. Europ. J. Pharmacol. 2, 187–192 (1968).CrossRefGoogle Scholar
  9. Carlton, P.L.: Potentiation of the behavioral effects of amphetamine by imipramine. Psychopharmacologia (Berl.) 2, 364–376 (1961).CrossRefGoogle Scholar
  10. —, and P. Didamo: Augmentation of the behavioral effect of amphetamine by atropine. J. Pharmacol. exp. Ther. 132, 91–96 (1961).PubMedGoogle Scholar
  11. Charpentier, J.: Modifications de la réaction à la douleur provoquées par diverses lésions cérébrales, et leurs effets sur la sensibilité à la morphine. Psychopharmacologia (Berl.) 11, 95–121 (1967).CrossRefGoogle Scholar
  12. Davey, M.J., J.B. Farmer, and H. Reinert: The effect of nialamide on adrenergic functions. Brit. J. Pharmacol. 20, 121–134 (1963).PubMedGoogle Scholar
  13. Dfbnick, B., G.A. Leeson, and G.E. Philipps: An effect of monoamine oxidase inhibitors on brain serotonin of mice in addition to that resulting from inhibition of monoamine oxidase. J. Neurochem. 9, 299–306 (1962).CrossRefGoogle Scholar
  14. Eibl-Eibesfeldt, I.: Grundriß der vergleichenden Verhaltensforschung, Ethologie. München: R. Piper u. Co. 1967.Google Scholar
  15. Everett, G.M.: Some electrophysiological and biochemical correlates of motor activity and aggressive behavior. In: Neuro-Psychopharmacology (Ed. E. Rothlin), Vol. 2, pp. 479–484. Amsterdam-London-New York-Princeton: Elsevier Publ. Co. 1961.Google Scholar
  16. —, and R.G. Wiegand: Central amines and behavioral states: a critique and new data. Proc. first Int. Pharmacol. Meet. Vol. 8, pp. 85–92. Oxford-London-New York-Paris: Pergamon Press 1962.Google Scholar
  17. — and F.U. Rinaldi: Pharmacologic studies of some nonhydrazine MAO inhibitors. Ann. N.Y. Acad. Sci. 107, 1068–1080 (1963).CrossRefGoogle Scholar
  18. Gessa, G.L., E. Cuenca, and E. Costa: On the mechanism of hypotensive effects of MAO inhibitors. Ann. N.Y. Acad. Sci. 107, 935–944 (1963).PubMedCrossRefGoogle Scholar
  19. Gey, K.F., A. Pletscher, and W. Burkard: Effect of inhibitors of monoamine oxidase on various enzymes and on the storage of monoamines. Ann. N.Y. Acad. Sci. 107, 1147–1151 (1963).PubMedCrossRefGoogle Scholar
  20. Goldberg, N.D., and F.E. Shideman: Species differences in the cardiac effects of a monoamine oxidase inhibitor. J. Pharmacol. exp. Ther. 136, 142–151 (1962).PubMedGoogle Scholar
  21. Goldstein, M., and K. Nakajima: Effect of disulfiram on catecholamine levels in the brain. J. Pharmacol. exp. Ther. 157, 96–102 (1967).PubMedGoogle Scholar
  22. Grant, E. C, and J.H. Mackintosh: A comparison of the social postures of some common laboratory rodents. Behaviour 21, 246–259 (1963).CrossRefGoogle Scholar
  23. Green, H., and R.W. Erickson: Further studies with tranylcypromine (monoamine oxidase inhibitor) and its interaction with reserpine in rat brain. Arch. int. Pharmacodyn. 135, 407–425 (1962).PubMedGoogle Scholar
  24. Gunne, L.-M., and T. Lewander: Monoamines in brain and adrenal glands of cats after electrically induced defense reaction. Acta physiol. scand. 67, 405–410 (1966).PubMedCrossRefGoogle Scholar
  25. Halliwell, G., R.M. Quinton, and F.E. Williams: A comparison of imipramine, chlorpromazine and related drugs in various tests involving autonomie functions and antagonism of reserpine. Brit. J. Pharmacol. 23, 330–350 (1964).PubMedGoogle Scholar
  26. Hanson, L.C.F.: Evidence that the central action of amphetamine is mediated via catecholamines. Psychopharmacologia (Berl.) 10, 289–297 (1967).CrossRefGoogle Scholar
  27. Harrer, G.: Zur Inkompatibilität zwischen Monoaminoxydase-Hemmern und Imipramin. Wien. med. Wschr. 111, 551–553 (1961).PubMedGoogle Scholar
  28. Himwich, W.A.: Interaction of monoamine oxidase inhibitors with imipramine and similar drugs. Rec. Advanc. biol. Psychiat. 4, 257–265 (1962).CrossRefGoogle Scholar
  29. Holtz, P., u. D. Palm: Brenzkatechinamine und andere sympathicomimetische Amine. Biosynthese und Inaktivierung, Freisetzung und Wirkung. Ergebn. Physiol. (Rev. Physiol.) 58, 1–580 (1966).CrossRefGoogle Scholar
  30. Horita, A., and W.R. McGrath: Specific liver and brain monoamine oxidase inhibition by alkyl-and arylalkylhydrazines. Proc. Soc. exp. Biol. (N.Y.) 103, 753–757 (1960).CrossRefGoogle Scholar
  31. Hornykiewicz, O., u. H.-J. Lisch: Monoaminoxydase-Hemmer und Dopamin-(3-Hydroxytyramin-)Stoffwechsel im Gehirn. Naunyn-Schmiedebergs Arch. Pharmak. exp. Path. 257, 30 (1967).CrossRefGoogle Scholar
  32. Huković, S., u. E. Muscholl: Die Noradrenalin-Abgabe aus dem isolierten Kaninchenherzen bei sympathischer Nervenreizung und ihre pharmakologische Beeinflussung. Naunyn-Schmiedebergs Arch. exp. Path. Pharmak. 244, 81–96 (1962).CrossRefGoogle Scholar
  33. Levy, L, et E. Michel-Ber: Commentaires sur l’interprétation pharmacologique des effets cliniques spécifiques et secondaires des inhibiteurs de la monoamine-oxydase. Actualités pharmacol. 18, 241–288 (1965).PubMedGoogle Scholar
  34. Ling, G.M., M. Nagai, and S. Hansen: Convulsive effects of tranylcypromine and imipramine in combination. Lancet 1961 II, 1262.CrossRefGoogle Scholar
  35. Loveless, A.H., and D.R. Maxwell: A comparison of the effects of imipramine, trimipramine, and some other drugs in rabbits treated with a monoamine oxidase inhibitor. Brit. J. Pharmacol. 25, 158–170 (1965).PubMedGoogle Scholar
  36. Luby, E.D., and E.F. Domino: Toxicity from large doses of imipramine and an MAO inhibitor in suicidal intent. J. Amer. med. Ass. 177, 68–69 (1961).CrossRefGoogle Scholar
  37. Matthies, H., u. N. Popov: Unterschiedliche Wirkungen von Monoaminoxydase-Hemmern unter den Bedingungen vollständiger Monoaminoxydase-Hemmung auf den Serotonin-, Dopamin-und Noradrenalin-Gehalt. Acta biol. med. germ. 17, 488–497 (1966).PubMedGoogle Scholar
  38. Moore, K.E., and R.H. Rech: Antagonism by monoamine oxidase inhibitors of α-methyltyrosine-induced catecholamine depletion and behavioral depression. J. Pharmacol. exp. Ther. 156, 70–75 (1967).PubMedGoogle Scholar
  39. Morpurgo, C: Aggressive behavior induced by large doses of 2-(2, 6-dichlorphenyl-amino)-2-imidazoline hydrochloride (ST 155) in mice. Europ. J. Pharmacol. 3, 374–377 (1968).CrossRefGoogle Scholar
  40. Nijdam, S.J.: Neurological and psychiatrical side-effects during treatment with modern psychotropic drugs. In: Drug induced Diseases, Symp., Leyden 1962 (L. Meyler and H.M. Peck, Ed.), pp. 211–228. Springfield, Ill.: Ch. C. Thomas 1962.Google Scholar
  41. Pepeu, G., M. Roberts, S. Schanberg, and N.J. Giarman: Differential of iproniazid (Marsilid) and beta-phenylisopropylhydrazine (Catron) on isolated atria. J. Pharmacol. exp. Ther. 132, 131–138 (1961).PubMedGoogle Scholar
  42. Pletscher, A.: Monoamine oxidase inhibitors. Pharmacol. Rev. 18, 121–129 (1966).PubMedGoogle Scholar
  43. — K.F. Gey, and W.P. Burkard: Inhibitors of monoamine oxidase and de-carboxylase of aromatic amino acids. In: Heffter’s Handb. exp. Pharmakol., Bd. 19, S. 593–735. Berlin-Heidelberg-New York: Springer 1966.Google Scholar
  44. — u. P. Zeller: Monoaminoxydase-Hemmer. Chemie, Biochemie, Pharmakologie, Klinik. Fortschr. Arzneimittel-Forsch. 2, 417–590 (1960).Google Scholar
  45. Randrup, A., and I. Munkvad: Dopa and other naturally occurring substances as causes of stereotypy and rage in rats. Acta psychiat. scand. (Suppl.) 191-192, 193-199 (1966).Google Scholar
  46. — Stereotyped activities produced by amphetamine in several animal species and man. Psychopharmacologia (Berl.) 11, 300–310 (1967).CrossRefGoogle Scholar
  47. Reis, D.J., and K. Fuxe: Depletion of noradrenaline in brainstem neurons during sham rage behaviour produced by acute brainstem transection in cat. Brain Res. 7, 448–451 (1968).PubMedCrossRefGoogle Scholar
  48. Scheel-Krüger, J., and A. Randrup: Stereotype hyperactive behaviour produced by dopamine in the absence of noradrenaline. Life Sci. 6, 1389–1398 (1967).PubMedCrossRefGoogle Scholar
  49. — Aggressive behaviour provoked by pargyline in rats pretreated with diethyldithiocarbamate. J. Pharm. Pharmacol. 20, 948–949 (1968).PubMedCrossRefGoogle Scholar
  50. Sjöqvist, F.: Psychotropic drugs (2). Interaction between monoamine oxidase (MAO) inhibitors and other substances. Proc. roy. Soc. Med. 58, 967–978 (1965).PubMedGoogle Scholar
  51. Spector, S., C.W. Hirsch, and B.B. Brodie: Association of behavioural effects of pargyline, a nonhydrazide MAO inhibitor with increase in brain norepinephrine. Int. J. Neuropharmacol. 2, 81–93 (1963).CrossRefGoogle Scholar
  52. — R. Kuntzmann, P.A. Shore, and B.B. Brodie: Evidence for release of brain amines by reserpine in presence of monoaminoxidase inhibitors: Implication of monoaminoxidase in norepinephrine metabolism in brain. J. Pharmacol. exp. Ther. 130, 256–261 (1960).Google Scholar
  53. Spector S., P.A. Shore, and B.B. Brodie: Biochemical and pharmacological effects of the monoamine oxidase inhibitors, iproniazid, 1-phenyl-2-hydrazinopropane (IB 516) and 1-phenyl-3-hydrazinobutane (IB 835). J. Pharmacol. exp. Ther. 128, 15–21 (1960).PubMedGoogle Scholar
  54. Sulser, F., M.L. Owens, M.R. Norvich, and I.V. Dingell: The relative role of storage and synthesis of brain norepinephrine in the psychomotor stimulation evoked by amphetamine or by desipramine and tetrabenazine. Psychopharmacologia (Berl.) 12, 322–332 (1968).CrossRefGoogle Scholar
  55. Valzelli, L.: Drugs and aggressiveness. Advanc. Pharmacol. 5, 79–108 (1967).CrossRefGoogle Scholar
  56. Vanni, P., et F. Riggi: Etude expérimentale des effets biologiques du tofranil associé aux inhibiteurs des MAO et aux neuroleptiques dans les animaux. Proc. 3rd Wld. Congr. Psychiat. Montreal, Vol. 11, pp. 929–932 (1961).Google Scholar
  57. Várszegi, K.M., and L. Decsi: Some characteristics of the rage reaction evoked by chemical stimulation of the hypothalamus. Acta physiol. Acad. Sci. hung. 32, 61–68 (1967).PubMedGoogle Scholar
  58. Votava, Z., S.N. Glisson, and H.E. Himwich: Behavioral reaction of rats pretreated with reserpine to LSD-25. Int. J. Neuropharmacol. 6, 543–547 (1967).PubMedCrossRefGoogle Scholar
  59. Zetler, G.: Cataleptic state and hypothermia in mice, caused by central cholinergic stimulation and antagonized by anticholinergic and antidepressant drugs. Int. J. Neuropharmacol. 7, 325–335 (1968).PubMedCrossRefGoogle Scholar
  60. Zirkle, C.L., and C. Kaiser: Monoamine oxidase inhibitors (nonhydrazines). In: Medicinal Chemistry, Psychopharmacological Agents, Vol. 4, 1, pp. 445–554 (ed. M. Gordon). New York-London: Acad. Press Inc. 1964.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1969

Authors and Affiliations

  • G. Zetler
    • 1
  • U. Otten
    • 1
  1. 1.Institut für PharmakologieMedizinischen AkademieLübeckDeutschland

Personalised recommendations